Roche (OTCMKTS:RHHBY) Reaches New 52-Week High – Should You Buy?

Shares of Roche Holding AG (OTCMKTS:RHHBY) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $51.67 and last traded at $51.43, with a volume of 2821543 shares trading hands. The stock had previously closed at $51.20.

Analyst Ratings Changes

Several research firms recently weighed in on RHHBY. HSBC reiterated a “buy” rating and set a $57.00 target price on shares of Roche in a research report on Wednesday, December 10th. Zacks Research downgraded Roche from a “hold” rating to a “strong sell” rating in a research note on Friday, December 5th. Hsbc Global Res raised Roche from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 2nd. JPMorgan Chase & Co. raised shares of Roche from an “underweight” rating to a “neutral” rating in a report on Monday, December 8th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Roche from a “sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Three equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $57.00.

Roche Stock Performance

The firm has a 50-day moving average of $45.95 and a 200-day moving average of $42.70.

Hedge Funds Weigh In On Roche

Hedge funds have recently modified their holdings of the stock. Diversified Trust Co grew its stake in Roche by 0.5% during the third quarter. Diversified Trust Co now owns 57,881 shares of the company’s stock valued at $2,363,000 after acquiring an additional 310 shares in the last quarter. Canopy Partners LLC grew its position in shares of Roche by 4.9% during the third quarter. Canopy Partners LLC now owns 7,580 shares of the company’s stock valued at $317,000 after purchasing an additional 352 shares in the last quarter. Everett Harris & Co. CA grew its position in shares of Roche by 3.5% during the second quarter. Everett Harris & Co. CA now owns 11,190 shares of the company’s stock valued at $456,000 after purchasing an additional 381 shares in the last quarter. Curio Wealth LLC bought a new stake in shares of Roche in the third quarter worth about $25,000. Finally, Confluence Investment Management LLC lifted its position in shares of Roche by 5.1% in the second quarter. Confluence Investment Management LLC now owns 15,225 shares of the company’s stock worth $621,000 after buying an additional 734 shares in the last quarter.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.